vs
Side-by-side financial comparison of OP Bancorp (OPBK) and Xilio Therapeutics, Inc. (XLO). Click either name above to swap in a different company.
OP Bancorp is the larger business by last-quarter revenue ($24.3M vs $13.7M, roughly 1.8× Xilio Therapeutics, Inc.). OP Bancorp produced more free cash flow last quarter ($23.4M vs $-2.1M).
OP Bancorp is the bank holding company for Open Bank, a community-oriented commercial bank headquartered in California, United States. It provides a full range of banking solutions including deposit accounts, commercial real estate loans, small business financing, and consumer lending products, primarily catering to small and medium-sized enterprises, local immigrant communities, and retail clients across Southern California.
Xilio Therapeutics is a clinical-stage biotechnology company dedicated to developing novel tumor-selective immunotherapies for cancer treatment. Its product pipeline features candidates engineered to trigger anti-tumor immune responses specifically inside tumor microenvironments, reducing systemic toxicities, and it primarily targets oncology patient populations in North America and other global markets.
OPBK vs XLO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $24.3M | $13.7M |
| Net Profit | — | $10.4M |
| Gross Margin | — | — |
| Operating Margin | 39.2% | -86.5% |
| Net Margin | — | 75.7% |
| Revenue YoY | 13.7% | — |
| Net Profit YoY | — | 179.1% |
| EPS (diluted) | $0.48 | $-3.74 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $24.3M | $13.7M | ||
| Q3 25 | $24.5M | $19.1M | ||
| Q2 25 | $23.7M | $8.1M | ||
| Q1 25 | $22.2M | $2.9M | ||
| Q4 24 | $21.3M | — | ||
| Q3 24 | $20.7M | — | ||
| Q2 24 | $20.4M | — | ||
| Q1 24 | $19.6M | — |
| Q4 25 | — | $10.4M | ||
| Q3 25 | $6.7M | $-16.3M | ||
| Q2 25 | $6.3M | $-15.8M | ||
| Q1 25 | $5.6M | $-13.3M | ||
| Q4 24 | — | — | ||
| Q3 24 | $5.4M | — | ||
| Q2 24 | $5.4M | — | ||
| Q1 24 | $5.2M | — |
| Q4 25 | 39.2% | -86.5% | ||
| Q3 25 | 39.5% | -10.1% | ||
| Q2 25 | 35.7% | -177.7% | ||
| Q1 25 | 34.6% | -472.7% | ||
| Q4 24 | 31.2% | — | ||
| Q3 24 | 36.5% | — | ||
| Q2 24 | 37.2% | — | ||
| Q1 24 | 37.1% | — |
| Q4 25 | — | 75.7% | ||
| Q3 25 | 27.4% | -85.4% | ||
| Q2 25 | 26.7% | -196.0% | ||
| Q1 25 | 25.0% | -452.7% | ||
| Q4 24 | — | — | ||
| Q3 24 | 26.2% | — | ||
| Q2 24 | 26.7% | — | ||
| Q1 24 | 26.7% | — |
| Q4 25 | $0.48 | $-3.74 | ||
| Q3 25 | $0.45 | $-0.11 | ||
| Q2 25 | $0.42 | $-0.16 | ||
| Q1 25 | $0.37 | $-0.18 | ||
| Q4 24 | $0.33 | — | ||
| Q3 24 | $0.36 | — | ||
| Q2 24 | $0.36 | — | ||
| Q1 24 | $0.34 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.3M | $137.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $227.9M | $35.3M |
| Total Assets | $2.7B | $154.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.3M | $137.5M | ||
| Q3 25 | $166.7M | $103.8M | ||
| Q2 25 | $205.4M | $121.6M | ||
| Q1 25 | $198.9M | $89.1M | ||
| Q4 24 | $134.9M | — | ||
| Q3 24 | $166.8M | — | ||
| Q2 24 | $127.7M | — | ||
| Q1 24 | $139.2M | — |
| Q4 25 | $227.9M | $35.3M | ||
| Q3 25 | $221.5M | $-8.1M | ||
| Q2 25 | $213.7M | $7.1M | ||
| Q1 25 | $210.1M | $10.7M | ||
| Q4 24 | $205.0M | — | ||
| Q3 24 | $203.6M | — | ||
| Q2 24 | $195.9M | — | ||
| Q1 24 | $194.7M | — |
| Q4 25 | $2.7B | $154.7M | ||
| Q3 25 | $2.6B | $133.7M | ||
| Q2 25 | $2.6B | $133.8M | ||
| Q1 25 | $2.5B | $103.7M | ||
| Q4 24 | $2.4B | — | ||
| Q3 24 | $2.4B | — | ||
| Q2 24 | $2.3B | — | ||
| Q1 24 | $2.2B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $26.2M | $-2.0M |
| Free Cash FlowOCF − Capex | $23.4M | $-2.1M |
| FCF MarginFCF / Revenue | 96.2% | -15.3% |
| Capex IntensityCapex / Revenue | 11.5% | 0.7% |
| Cash ConversionOCF / Net Profit | — | -0.19× |
| TTM Free Cash FlowTrailing 4 quarters | $43.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $26.2M | $-2.0M | ||
| Q3 25 | $23.9M | $-17.5M | ||
| Q2 25 | $-7.0M | $-14.5M | ||
| Q1 25 | $5.6M | $29.0M | ||
| Q4 24 | $31.2M | — | ||
| Q3 24 | $13.3M | — | ||
| Q2 24 | $15.8M | — | ||
| Q1 24 | $-3.2M | — |
| Q4 25 | $23.4M | $-2.1M | ||
| Q3 25 | $23.4M | — | ||
| Q2 25 | $-7.7M | $-14.9M | ||
| Q1 25 | $4.2M | $29.0M | ||
| Q4 24 | $29.7M | — | ||
| Q3 24 | $12.8M | — | ||
| Q2 24 | $15.7M | — | ||
| Q1 24 | $-3.2M | — |
| Q4 25 | 96.2% | -15.3% | ||
| Q3 25 | 95.6% | — | ||
| Q2 25 | -32.5% | -184.0% | ||
| Q1 25 | 19.0% | 988.3% | ||
| Q4 24 | 139.0% | — | ||
| Q3 24 | 61.5% | — | ||
| Q2 24 | 77.0% | — | ||
| Q1 24 | -16.6% | — |
| Q4 25 | 11.5% | 0.7% | ||
| Q3 25 | 2.3% | 0.0% | ||
| Q2 25 | 3.0% | 5.0% | ||
| Q1 25 | 6.4% | 0.8% | ||
| Q4 24 | 7.3% | — | ||
| Q3 24 | 2.8% | — | ||
| Q2 24 | 0.4% | — | ||
| Q1 24 | 0.5% | — |
| Q4 25 | — | -0.19× | ||
| Q3 25 | 3.57× | — | ||
| Q2 25 | -1.10× | — | ||
| Q1 25 | 1.02× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.45× | — | ||
| Q2 24 | 2.90× | — | ||
| Q1 24 | -0.60× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
